Chemoprevention of Prostate Cancer

Amanda Beth Reed, Kristin C. Reed, Dipen J Parekh

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Purpose of Review. We examine the role of chemotherapeutic agents in the prevention of prostate cancer and analyze the phase III clinical trials investigating the application of these agents for prostate cancer. Recent Findings, There are two reported phase III randomized clinical trials which evaluate the role of chemotherapeutic agents in the prevention of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) originally revealed that finasteride reduced the risk of prostate cancer by approximately 25% versus placebo but patients who received finasteride had a greater incidence of high grade tumors. Recent updates of the PCPT confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to improvement the performance characteristics of PSA and prostate biopsy to improve cancer detection. The SELECT trial evaluated the roles of selenium and vitamin E in the prevention of prostate cancer, but found no benefit of either supplement, Chemoprevention of prostate cancer is now possible with finasteride. An ancillary benefit includes an enhancement in detection of high grade, potentially fatal, prostate cancer.

Original languageEnglish
Title of host publicationEvidence-Based Urology
PublisherWiley-Blackwell
Pages236-242
Number of pages7
ISBN (Print)9781405185943
DOIs
StatePublished - Jul 9 2010
Externally publishedYes

Fingerprint

Chemoprevention
Prostatic Neoplasms
Finasteride
Phase III Clinical Trials
Neoplasms
Selenium
Vitamin E
Prostate
Randomized Controlled Trials
Placebos
Biopsy
Incidence

Keywords

  • 5-alpha reductase inhibitor
  • Chemoprevention
  • Finasteride
  • Prostate cancer
  • Selenium
  • Vitamin E

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reed, A. B., Reed, K. C., & Parekh, D. J. (2010). Chemoprevention of Prostate Cancer. In Evidence-Based Urology (pp. 236-242). Wiley-Blackwell. https://doi.org/10.1002/9781444323146.ch25

Chemoprevention of Prostate Cancer. / Reed, Amanda Beth; Reed, Kristin C.; Parekh, Dipen J.

Evidence-Based Urology. Wiley-Blackwell, 2010. p. 236-242.

Research output: Chapter in Book/Report/Conference proceedingChapter

Reed, AB, Reed, KC & Parekh, DJ 2010, Chemoprevention of Prostate Cancer. in Evidence-Based Urology. Wiley-Blackwell, pp. 236-242. https://doi.org/10.1002/9781444323146.ch25
Reed AB, Reed KC, Parekh DJ. Chemoprevention of Prostate Cancer. In Evidence-Based Urology. Wiley-Blackwell. 2010. p. 236-242 https://doi.org/10.1002/9781444323146.ch25
Reed, Amanda Beth ; Reed, Kristin C. ; Parekh, Dipen J. / Chemoprevention of Prostate Cancer. Evidence-Based Urology. Wiley-Blackwell, 2010. pp. 236-242
@inbook{4b6a36f0e284438eac4977a3a5e0556d,
title = "Chemoprevention of Prostate Cancer",
abstract = "Purpose of Review. We examine the role of chemotherapeutic agents in the prevention of prostate cancer and analyze the phase III clinical trials investigating the application of these agents for prostate cancer. Recent Findings, There are two reported phase III randomized clinical trials which evaluate the role of chemotherapeutic agents in the prevention of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) originally revealed that finasteride reduced the risk of prostate cancer by approximately 25{\%} versus placebo but patients who received finasteride had a greater incidence of high grade tumors. Recent updates of the PCPT confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to improvement the performance characteristics of PSA and prostate biopsy to improve cancer detection. The SELECT trial evaluated the roles of selenium and vitamin E in the prevention of prostate cancer, but found no benefit of either supplement, Chemoprevention of prostate cancer is now possible with finasteride. An ancillary benefit includes an enhancement in detection of high grade, potentially fatal, prostate cancer.",
keywords = "5-alpha reductase inhibitor, Chemoprevention, Finasteride, Prostate cancer, Selenium, Vitamin E",
author = "Reed, {Amanda Beth} and Reed, {Kristin C.} and Parekh, {Dipen J}",
year = "2010",
month = "7",
day = "9",
doi = "10.1002/9781444323146.ch25",
language = "English",
isbn = "9781405185943",
pages = "236--242",
booktitle = "Evidence-Based Urology",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Chemoprevention of Prostate Cancer

AU - Reed, Amanda Beth

AU - Reed, Kristin C.

AU - Parekh, Dipen J

PY - 2010/7/9

Y1 - 2010/7/9

N2 - Purpose of Review. We examine the role of chemotherapeutic agents in the prevention of prostate cancer and analyze the phase III clinical trials investigating the application of these agents for prostate cancer. Recent Findings, There are two reported phase III randomized clinical trials which evaluate the role of chemotherapeutic agents in the prevention of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) originally revealed that finasteride reduced the risk of prostate cancer by approximately 25% versus placebo but patients who received finasteride had a greater incidence of high grade tumors. Recent updates of the PCPT confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to improvement the performance characteristics of PSA and prostate biopsy to improve cancer detection. The SELECT trial evaluated the roles of selenium and vitamin E in the prevention of prostate cancer, but found no benefit of either supplement, Chemoprevention of prostate cancer is now possible with finasteride. An ancillary benefit includes an enhancement in detection of high grade, potentially fatal, prostate cancer.

AB - Purpose of Review. We examine the role of chemotherapeutic agents in the prevention of prostate cancer and analyze the phase III clinical trials investigating the application of these agents for prostate cancer. Recent Findings, There are two reported phase III randomized clinical trials which evaluate the role of chemotherapeutic agents in the prevention of prostate cancer. The Prostate Cancer Prevention Trial (PCPT) originally revealed that finasteride reduced the risk of prostate cancer by approximately 25% versus placebo but patients who received finasteride had a greater incidence of high grade tumors. Recent updates of the PCPT confirmed that finasteride reduces the risk of clinically significant prostate cancer, including high-grade tumors, primarily due to improvement the performance characteristics of PSA and prostate biopsy to improve cancer detection. The SELECT trial evaluated the roles of selenium and vitamin E in the prevention of prostate cancer, but found no benefit of either supplement, Chemoprevention of prostate cancer is now possible with finasteride. An ancillary benefit includes an enhancement in detection of high grade, potentially fatal, prostate cancer.

KW - 5-alpha reductase inhibitor

KW - Chemoprevention

KW - Finasteride

KW - Prostate cancer

KW - Selenium

KW - Vitamin E

UR - http://www.scopus.com/inward/record.url?scp=84885542389&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885542389&partnerID=8YFLogxK

U2 - 10.1002/9781444323146.ch25

DO - 10.1002/9781444323146.ch25

M3 - Chapter

SN - 9781405185943

SP - 236

EP - 242

BT - Evidence-Based Urology

PB - Wiley-Blackwell

ER -